Zinc metalloproteins as medicinal targets

Chemical Society Reviews

Volumn 37, Issue 8, 2008, Pages 1629-1651

  Anzellotti, A I ^a   Farrell, N P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 47749124645     PISSN: 03060012     EISSN: 14604744     Source Type: Journal    
DOI: 10.1039/b617121b     Document Type: Article

References (162)

1. C. Andreini, L. Banci, I. Bertini, A. Rosato, “Counting the zinc-proteins encoded in the human genome” J. Proteome Res. 2005, 5, 196-201.
2. G. Parkin, “Synthetic analogues relevant to the structure and function of zinc enzymes” Chem. Rev. 2004, 104, 699-767.
3. W. N. Lipscomb, N. Sträter, “Recent advances in zinc enzymology” Chem. Rev. 1996, 96, 2375-2433.
4. W. Shi, C. Zhan, A. Ignatov, B. Manjasetty, N. Marinkovic, M. Sullivan, R. Huang, M. Chance, “Metalloproteomics: high-throughput structural and functional annotation of proteins in structural genomics” Structure, 2005, 13, 1473-1486.
5. A. Turner, “Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries” Biochem. Soc. Trans. 2003, 31, 723-727.
6. J. Laity, B. M. Lee, P. Wrigth, “Zinc finger proteins: new insights into structural and functional diversity” Curr. Opin. Struct. Biol. 2001, 11, 39-46.
7. D. S. Auld, “Zinc coordination sphere in biochemical zinc sites” BioMetals, 2001, 14, 271-313.
8. E. Mocchegiani, C. Bertoni-Freddari, F. Marcellini, M. Malavolta, Prog. Neurobiol. 2005, 75, 367-390.
9. S. C. Burdette, S. Lippard, “Meeting of the minds: metalloneurochemistry” Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 3605-3610.
10. C. J. Frederickson, A. Bush, “Synaptically released zinc: physiological functions and pathological effects” BioMetals, 2001, 14, 353-366.
11. A. Takeda, “Zinc homeostasis and functions of zinc in the brain” BioMetals, 2001, 14, 343-351.
12. M. Stefanidou, C. Maravelias, A. Dona, C. Spiliopoulou, “Zinc: a multipurpose trace element” Arch. Toxicol. 2006, 80, 1-9.
13. B. L. Vallee, K. Falchuk, “The biochemical basis of zinc physiology” Physiol. Rev. 1993, 73, 79-118.
14. P. Jiang, Z. Guo, “Fluorescent detection of zinc in biological systems: recent development on the design of chemosensors and biosensors” Coord. Chem. Rev. 2004, 248, 205-229.
15. W. Stocker, W. Bode, “Structural features of a superfamily of zinc-endopeptidases: the metzincins” Curr. Opin. Struct. Biol. 1995, 5, 383-390.
16. F. Gomis-Ruth, “Structural aspects of the metzincin clan of metalloendopeptidases” Mol. Biotechnol. 2003, 24, 157-202.
17. K. Maskos, W. Bode, “Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases” Mol. Biotechnol. 2003, 25, 241-266.
18. H. Nagase, R. Visse, G. Murphy, “Structure and function of matrix metalloproteinases and TIMPs” Cardiovasc. Res. 2006, 69, 562-573.
19. C. E. Brinckerhoff, L. Matrisian, “Matrix metalloproteinases: a tail of a frog that became a prince” Nat. Rev. Mol. Cell Biol. 2002, 3, 207-214.
20. E. I. Deryugina, J. P. Quigley, “Matrix metalloproteinases and tumor metastasis” Cancer Metastasis Rev. 2006, 25, 9-34.
21. G. Murphy, M. Lee, “What are the roles of metalloproteinases in cartilage and bone damage?” Ann. Rheum. Dis. 2005, 64, 44-47.
22. P. T. G. Elkington, C. M. O’kane, J. Friedland, “The paradox of matrix metalloproteinases in infectious disease” Clin. Exp. Immunol. 2005, 142, 12-20.
23. R. Chirco, X.-W. Liu, K.-K. Jung, H.-R. C. Kim, “Novel functions of TIMPs in cell signaling” Cancer Metastasis Rev. 2006, 25, 99-113.
24. C. Fernandez-Catalan, W. Bode, R. Huber, D. Turk, J. J. Calvete, A. Lichte, H. Tschesche, K. Maskos, “Crystal Structure of the MT1-MMP-TIMP-2 complex” EMBO J. 1998, 17, 5238-5248.
25. B. Pirard, “Insight into the structural determinants for selective inhibition of matrix metalloproteinases” Drug Discovery Today, 2007, 12, 640-646.
26. C. M. Overall, O. Kleifield, “Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy” Nat. Rev. Cancer, 2006, 6, 227-239.
27. I. Bertini, V. Calderone, M. Cosenza, M. Fragai, Y.-M. Lee, C. Luchinat, S. Mangani, B. Terni, P. Turano, “Conformational variability of matrix metalloproteinases: beyond a single 3D structure” Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 5334-5339.
28. A. Baker, R. E. Dylan, G. Murphy, “Metalloproteinase inhibitors: biological actions and therapeutic opportunities” J. Cell Sci. 2002, 115, 3719-3727.
29. J. A. Blagg, M. C. Noe, L. A. Wolf-Gouveia, L. A. Reiter, E. R. Laird, S.-P. P. Chang, D. E. Danley, J. T. Downs, N. C. Elliott, J. D. Eskra, R. J. Griffiths, J. R. Hardink, A. I. Haugeto, C. S. Jones, J. L. Liras, L. L. Lopresti-Morrow, P. G. Mitchell, J. Pandit, R. P. Robinson, C. Subramanyam, M. L. Vaughn-Bowser, S. A. Yocum, “Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14” Bioorg. Med. Chem. Lett. 2005, 15, 1807-1810.
30. D. T. Puerta, M. O. Griffin, J. A. Lewis, D. Romero-Perez, R. Garcia, F. J. Villareal, S. M. Cohen, “Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity and reactivity” JBIC, J. Biol. Inorg. Chem. 2006, 11, 131-138.
31. D. T. Puerta, J. Mongan, Tran, L. J. Ba, A. McCammon, S. M. Cohen, “Potent, selective pyrone-based inhibitors of stromelysin-1” J. Am. Chem. Soc. 2005, 127, 41, 14148-14149.
32. C. M. Overall, O. Kleifeld, “Towards third generation matrix metalloproteinases inhibitors for cancer therapy” Br. J. Cancer, 2006, 94, 941-946.
33. P. J. Dyson, G. Sava, “Metal-based antitumour drugs in the post genomic era” Dalton Trans. 2006, 1929-1933.
34. R. Sasanelli, A. Boccarelli, D. Giordano, M. Laforgia, F. Arnesano, G. Natile, C. Cardellicchio, M. A. M. Capozzi, M. Coluccia, “Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9 and 12” J. Med. Chem. 2007, 50, 15, 3434-3441.
35. C. B. Yoo, P. A. Jones, “Epigenetic therapy of cancer: past, present and future” Nat. Rev. Drug Discovery, 2006, 5, 37-50.
36. M. S. Cosgrove, C. Wolberger, “How does the histone code work?” Biochem. Cell Biol. 2005, 83, 468-476.
37. A. Minucci, G. Pelicci, “Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer” Nat. Rev. Cancer, 2006, 6, 38-51.
38. A. Vannini, C. Volpari, G. Filocamo, E. C. Casavola, M. Brunetti, D. Renzoni, P. Chakravarty, C. Paolini, R. De Francesco, P. Gallinari, C. Steinkühler, S. Di Marco, “Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor” Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 15064-15069.
39. M. S. Finnin, J. R. Donigian, A. Cohen, V. M. Richon, R. A. Rifkind, P. A. Marks, R. Breslow, N. P. Pavletich, “Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors” Nature, 1999, 401, 188-193.
40. K. Vanommeslaeghe, F. De Proft, S. Loverix, D. Tourwé, P. Geerlings, “Theoretical study revealing the functioning of a novel combination of catalytic motifs in histone deacetylase” Bioorg. Med. Chem. 2005, 13, 3987-3992.
41. C. Corminboeuf, P. Hu, M. E. Tuckermann, Y. Zhang, “Unexpected deacetylation mechanism suggested by a density functional theory QM/MM study of histone-deacetylase-like protein” J. Am. Chem. Soc. 2006, 128, 4530-4531.
42. L. Z. He, T. Tolentino, P. Grayson, S. Zhong, R. P. Warrell, Jr. R. A. Rifkind, P. A. Marks, V. M. Richon, P. P. Pandolfi, “Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia” J. Clin. Invest. 2001, 108, 1321-1330.
43. M. R. Acharya, A. Sparreboom, J. Venitz, W. D. L. Figg, “Rational development of histone deacetylase inhibitors as anticancer agents: A review” Mol. Pharmacol. 2005, 68, 917-932.
44. T. Liu, S. Kuljaca, A. Tee, G. M. Marshall, “Histone deacetylase inhibitors: multifunctional anticancer agents” Cancer Treat. Rev. 2006, 32, 157-165.
45. R. N. Saha, K. Pahan, “HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis” Cell Death Differ. 2006, 13, 539-550.
46. F. Blanchard, C. Chipoy, “Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?” Drug Discovery Today, 2005, 10, 197-204.
47. M. Dokmanovic, P. A. Marks, “Prospects: histone deacetylase inhibitors” J. Cell. Biochem. 2005, 96, 293-304.
48. C. Monneret, “Histone deacetylase inhibitors” Eur. J. Med. Chem. 2005, 40, 1-13.
49. D. C. Drummond, C. O. Noble, D. B. Kirpotin, Z. Guo, G. K. Scott, C. C. Benz, Annu. Rev. Pharmacol. Toxicol. 2004, 45, 495-528.
50. N. Carey, N. B. La Thangue, “Histone deacetylase inhibitors: gathering pace” Curr. Opin. Pharmacol. 2006, 6, 369-375.
51. W. Gu, I. Nusinzon, R. D. Smith Jr, C. M. Horvath, R. B. Silverman, “Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: potent inhibition of histone deacetylases” Bioorg. Med. Chem. 2006, 14, 3320-3329.
52. M. V. Simonini, L. M. Camargo, E. Dong, E. Maloku, M. Veldic, E. Costa, A. Guidotti, “The benzamine MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases” Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 1587-1592.
53. Q. Lu, Y.-T. Yang, C.-S. Chen, M. Davis, J. C. Byrd, M. R. Etherton, A. Umar, C.-S. Chen, “Zn2+-Chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors” J. Med. Chem. 2004, 47, 467-474.
54. M. P. I. Bhuiyan, T. Kato, T. Okauchi, N. Nishino, S. Maeda, T. G. Nishino, M. Yoshida, “Chlamydocin analogs bearing carbonyl groups as possible ligand towards zinc atom in histone deacetylases” Bioorg. Med. Chem. 2006, 14, 3438-3446.
55. P. A. Marks, X. Jiang, “Histone deacetylase inhibitors in programmed cell death and cancer therapy” Cell Cycle, 2005, 4, 549-551.
56. P.-H. Liang, T.-P. Ko, A. H.-J. Wang, “Structure, mechanism and function of prenyltransferases” Eur. J. Biochem. 2002, 269, 3339-3354.
57. S. Maurer-Stroh, S. Washietl, F. Eisenhaber, “Protein prenyltransferases” GenomeBiology, 2003, 4, 212.
58. S. F. Sousa, P. A. Fernandes, M. J. Ramos, “Unravelling the mechanism of the arnesyltransferase enzyme” JBIC, J. Biol. Inorg. Chem. 2005, 10, 3-10.
59. T. B. Brunner, S. M. Hahn, A. K. Gupta, R. J. Muschel, W. G. McKenna, E. J. Bernhard, “Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations” Cancer Res. 2003, 63, 5656-5668.
60. S. B. Long, P. J. Casey, L. S. Beese, “Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate” Biochemistry, 1998, 37, 27, 9612-9618.
61. J. S. Taylor, T. S. Reid, K. L. Terry, P. J. Casey, L. S. Beese, “Structure of mammalian protein geranylgeranyltransferase type-I” EMBO J. 2003, 22, 22, 5963-5974.
62. H. Zhang, M. C. Seabra, J. Deisenhofer, “Crystal structure of Rab geranylgeranyltransferase at 2.0 A resolution” Structure, 2003, 8, 3, 241-251.
63. N. M. G. M. Appels, J. H. Beijnen, J. H. M. Schellens, “Development of farnesyl transferase inhibitors: a review” Oncologist, 2005, 10, 565-578.
64. V. Santagada, G. Caliendo, B. Severino, A. Lavecchia, E. Perisutti, F. Fiorino, A. Zampella, V. Sepe, D. Califano, G. Santelli, E. Novellino, “Synthesis, pharmacological evaluation, and molecular modeling studies of novel peptidic CAAX analogues as farnesyl-protein-transferase Inhibitors” J. Med. Chem. 2006, 49, 1882-1890.
65. A. D. Basso, P. Kirschmeier, R. Bishop, “Farnesyl transferase inhibitors” J. Lipid Res. 2006, 47, 15-31.
66. R. T. Eastman, F. S. Buckner, K. Yokoyama, M. H. Gelb, W. C. Van Voorhis, “Fighting parasitic disease by blocking protein farnesylation” J. Lipid Res. 2006, 47, 233-240.
67. T. S. Reid, S. B. Long, L. S. Beese, “Human protein farnesyltransferase complexed with L-778123 and FPP” Biochemistry, 2004, 43, 9000-9008.
68. J. M. Thomson, R. A. Bonomo, “The threat of antibiotic resistance in Gram-negative pathogenic bacteria: β-lactams in peril!” Curr. Opin. Microbiol. 2005, 8, 518-524.
69. M. S. Helfand, R. A. Bonomo, “Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum β-lactamases and metallo-β-lactamases on the treatment of resistant Gram-negative pathogens” Curr. Opin. Pharmacol. 2005, 5, 452-458.
70. C. Bebrone, “Metallo-β-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily” Biochem. Pharmacol. 2007, 74, 1686-1701.
71. J. D. Garrity, B. Bennett, M. W. Crowder, “Direct evidence that the reaction intermediate of metallo-β-lactamase L1 is metal bound” Biochemistry, 2005, 44, 1078-1087.
72. D. Xu, D. Xie, H. Guo, “Catalytic mechanism of class B2 metallo-β-lactamase” J. Biol. Chem. 2006, 281, 8740-8747.
73. G. Garau, C. Bebrone, C. Anne, M. Galleni, Frère, O. Dideberg, “A metallo-β-lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with Biapenem” J. Mol. Biol. 2003, 345, 785-795.
74. S. B. Levy, “Antibiotic resistance-the problem intensifies” Adv. Drug Delivery Rev. 2005, 57, 1446-1450.
75. T. R. Fritsche, H. S. Sader, M. A. Toleman, T. R. Walsh, R. N. Jones, “Emerging metallo-β-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program” Clin. Infect. Dis. 2005, 41, S276-S278.
76. J. H. Toney, J. G. Moloughney, “Metallo-β-lactamase inhibitors: promise for the future” Curr. Opin. Invest. Drugs, 2004, 5, 8, 823-826.
77. H. Kurosaki, Y. Yamaguchi, T. Higashi, K. Soga, S. Matsueda, H. Yumoto, S. Misumi, Y. Yamagata, Y. Arakawa, M. Goto, “Irreversible inhibition of metallo-β-lactamase (IMP-1) by 3-(3-mercaptopropionylsulfanyl)-propionic acid pentafluorophenyl ester” Angew. Chem. Int. Ed. 2005, 44, 3861-3864.
78. J. Spencer, T. R. Walsh, “A new approach to the inhibition of metallo-β-lactamases” Angew. Chem. Int. Ed. 2006, 45, 1022-1026.
79. A. I. Bush, C. C. Curtain, “Twenty years of metallo-neurobiology where to now?” Eur. Biophys. J. 2008, 37, 241-245.
80. P. J. Hart, “Pathogenic superoxide dismutase structure, folding, aggregation and turnover” Curr. Opin. Chem. Biol. 2006, 10, 131-138.
81. R. Noor, S. Mittal, J. Iqbal, “Superoxide dismutase – applications and relevance to human diseases” Med. Sci. Monit. 2002, 8, 9, RA210-215.
82. D. P. Riley, “Functional mimics of superoxide dismutase enzymes as therapeutic agents” Chem. Rev. 1999, 99, 9, 2573-2588.
83. E. A. Hileman, G. Achanta, P. Huang, “Superoxide dismutase: an emerging target for cancer therapeutics” Expert Opin. Ther. Targets, 2001, 5, 697-710.
84. S. Z. Potter, J. S. Valentine, “The perplexing role of copper–zinc superoxide dismutase in amyotrophic lateral sclerosis (Lou Gehrig's disease)” JBIC, J. Biol. Inorg. Chem. 2003, 8, 4, 373-380.
85. A. F. Miller, “Superoxide dismutases: active sites that save, but a protein that kills” Curr. Opin. Chem. Biol. 2004, 8, 162-168.
86. D. Medinas, O. Augusto, “Zinc-deficient SOD possesses increased peroxidase and thiol oxidase activity” Free Radical Biol. Med. 2005, 39, S26-S27.
87. J. S. Valentine, P. J. Hart, “Misfolded CuZnSOD and amyotrophic lateral sclerosis” Proc. Natl. Acad. Sci. U. S. A. 2003, 101, 15094-15099.
88. S. D. Khare, M. Caplow, N. V. Dokholyan, “The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amytrophic lateral sclerosis” Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 15094-15099.
89. K. A. Vassall, P. B. Stathopulos, J. A. O. Rumfeldt, J. R. Lepock, E. M. Meiering, “Equilibrium thermodynamic analysis of amyotrophic lateral sclerosis-associated mutant Apo Cu, Zn superoxide dismutases” Biochemistry, 2006, 45, 7366-7379.
90. F. Zhang, H. Zhu, “Intracellular conformational alterations of mutant SOD1 and the implications for fALS-associated SOD1 induced motor neuron cell death” Biochim. Biophys. Acta, 2006, 1760, 404-414.
91. Y. Furukawa, T. V. O’halloran, “Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo- and reduced form of SOD-1, leading to unfolding and oxidative aggregation” J. Mol. Biol. 2005, 280, 17266-17274.
92. J. A. Rodriguez, B. F. Shaw, A. Durazo, A. H. Sohn, P. A. Doucette, A. M. Nersissian, K. F. Faull, D. K. Eggers, A. Tiwari, L. J. Hayward, J. S. Valentine, “Destabilization of apoprotein is insufficient to explain Cu, Zn-superoxide dismutase-linked ALS pathogenesis” Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 10516-10521.
93. S. M. Lynch, W. Colón, “Dominant role of copper in the kinetics stability of Cu/Zn superoxide dismutase” Biochem. Biophys. Res. Commun. 2006, 340, 457-461.
94. Y. Furukawa, R. Fu, H.-X. Deng, T. Siddique, T. V. O’halloran, “Disulfide cross-linked protein represents a significant fraction of ALS-associated Cu, Zn-superoxide dismutase aggregates in spinal cords of model mice” Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 7148-7153.
95. A. Nordlund, M. Oliveberg, “Folding of Cu/Zn superoxide dismutase suggests structural hotspots for gain of neurotoxic function in ALS: parallels to precursors in amyloid disease” Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 10218-10223.
96. S. S. Ray, R. J. Nowak, R. H. Brown Jr, P. T. Lansbury Jr, “Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation” Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 3639-3644.
97. M. T. Carri, G. Grignaschi, C. Bendotti, “Target in ALS: designing multidrug therapies” Trends Pharmacol. Sci. 2006, 27, 267-273.
98. J. M. Bhatt, P. H. Gordon, Expert Opin. Invest. Drugs, 2007, 16, 1197-1207.
99. F. Sugai, Y. Yamamoto, K. Miyaguchi, Z. Zhou, H. Sumi, T. Hamasaki, M. Goto, S. Sakoda, “Benefit of valproic acid in suppressing disease progression of ALS model mice” Eur. J. Neurosci. 2004, 20, 3179-3183.
100. B. M. Todorich, J. R. Connor, “Redox metals in Alzheimer’s disease” Ann. N. Y. Acad. Sci. 2004, 1012, 171-178.
101. P. J. Crouch, A. R. White, A. I. Bush, “The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer’s disease” FEBS J. 2007, 274, 3775-3783.
102. J. Miller, A. D. McLachlan, A. Klug, “Repetitive zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes” EMBO J. 1985, 4, 1609-1614.
103. M. J. Lachenmann, J. E. Ladbury, J. Dong, K. Huang, P. Carey, M. A. Weiss, “Why zinc fingers prefer zinc: ligand-field symmetry and the hidden thermodynamics of metal ion selectivity” Biochemistry, 2004, 43, 13910-13925.
104. E. Bombarda, B. P. Roques, Y. Mély, E. Grell, “Mechanism of zinc coordination by point-mutated structures of the distal CCHC binding motif of the HIV-1 NCp7 protein” Biochemistry, 2005, 44, 7315-7325.
105. A. Nomura, Y. Sugiura, “Contribution of individual zinc ligands to metal binding and peptide folding of zinc finger peptides” Inorg. Chem. 2002, 41, 3693-3698.
106. A. Bateman, E. Birney, L. Cerruti, R. Durbin, L. Etwiller, S. R. Eddy, S. Griffiths-Jones, K. L. Howe, M. Marshall, E. L. L. Sonnhammer, “The pfam protein families database” Nucleic Acids Res. 2002, 30, 276-280.
107. W. Maret, “Exploring the zinc proteome” J. Anal. At. Spectrom. 2004, 19, 15-19.
108. S. S. Krishna, I. Majumdar, N. V. Grishin, “Structural classification of zinc fingers” Nucleic Acids Res. 2003, 31, 532-550.
109. S. Oka, Y. Shiraishi, T. Yoshida, T. Ohkubo, Y. Sugiura, Y. Kobayashi, “NMR structure of transcription factor Sp1 DNA binding domain” Biochemistry, 2004, 43, 51, 16027-16035.
110. N. Morellet, H. de Rocquigny, Y. Mely, N. Jullian, H. Demene, M. Ottmann, D. Gerard, J. L. Darlix, M. C. Fournie-Zaluski, B. P. Roques, “Conformational behaviour of the active and inactive forms of the nucleocapsid NCp7 of HIV-1 studied by 1H NMR” J. Mol. Biol. 1994, 235, 1, 287-301.
111. L. C. Myers, G. L. Verdine, G. Wagner, “Solution structure of the DNA methyl phosphotriester repair domain of Escherichia coli Ada” Biochemistry, 1993, 32, 51, 14089-14094.
112. F. He, T. Umehara, K. Tsuda, M. Inoue, T. Kigawa, T. Matsuda, T. Yabuki, M. Aoki, E. Seki, T. Terada, M. Shirouzu, A. Tanaka, S. Sugano, Y. Muto, S. Yokoyama, “Solution structure of the zinc finger HIT domain in protein FON” Protein Sci. 2007, 16, 1577-1587.
113. M. Dhanasekaran, S. Negi, Y. Sugiura, “Designer zinc finger proteins: tools for creating artificial DNA-binding functional proteins” Acc. Chem. Res. 2006, 39, 45-52.
114. D. Jantz, B. T. Amann, G. J. Gatto, J. M. Berg, “The design of functional DNA-binding proteins based on zinc finger domains” Chem. Rev. 2004, 104, 789-799.
115. T. M. T. Hall, “Multiple roles of RNA recognition by zinc finger proteins” Curr. Opin. Struct. Biol. 2005, 15, 367-373.
116. N. Morellet, H. Demene, V. Teilleux, T. Huynh-Dinh, H. De Rocquigny, M.-C. Fournie-Zaluski, B. P. Roques, “Structure of the complex between the HIV-1 nucleocapsid protein NCp7 and the single-stranded pentanucleotide d(ACGCC)” J. Mol. Biol. 1998, 283, 2, 419-434.
117. R. N. De Guzman, Z. R. Wu, C. C. Stalling, L. Pappalardo, P. N. Borer, M. F. Summers, “Structure of the HIV-1 nucleocapsid protein bound to the SL3 Ψ-RNA recognition element” Science, 1998, 279, 384-388.
118. A. Klug, “Towards therapeutic applications of engineered zinc finger proteins” FEBS Lett. 2005, 579, 892-894.
119. T. Cathomen, M. D. Weitzman, “Pointing the finger at genetic disease” Gene Ther. 2005, 12, 1415-1416.
120. M. H. Porteus, D. Carroll, “Gene targeting using zinc finger nucleases” Nat. Biotechnol. 2005, 23, 967-973.
121. M. Papworth, M. Moore, M. Isalan, M. Minczuk, Y. Choo, A. Klug, “Inhibition of herpes simplex virus 1 gene expression by designer zinc-finger transcription factors” Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 1621-1626.
122. Y.-S. Kim, J.-M. Kim, D.-L. Jung, J.-E. Kang, S. Lee, J. S. Kim, W. Seol, H.-C. Shin, H. S. Kwon, C. Van Lint, N. Hernandez, M.-W. Hur, “Artificial zinc finger fusions targeting Sp1-binding sites and the trans-activator-responsive element potently repress transcription and replication of HIV-1” J. Biol. Chem. 2005, 280, 21545-21552.
123. G. Lomberk, R. Urrutia, “The family feud: turning off Sp1 by Sp1-like KLF proteins” Biochem. J. 2005, 392, 1-11.
124. S. Safe, M. Abdelrahim, “Sp transcription factor family and its role in cancer” Eur. J. Cancer, 2005, 41, 2438-2448.
125. C. S. Hunter, S. J. Rhodes, “LIM-homeodomain genes in mammalian development and human disease” Mol. Biol. Rep. 2005, 32, 67-77.
126. A. Witkiewicz-Kucharczyk, W. Bal, “Damage of zinc fingers in DNA repair proteins, a novel molecular mechanism in carcinogenesis” Toxicol. Lett. 2006, 162, 29-42.
127. F. Evanics, L. Maurmann, W. W. Yang, R. N. Bose, “Nuclear magnetic resonance structures of the zinc-finger domain of human DNA polymerase-α” Biochim. Biophys. Acta, 2003, 1651, 163-171.
128. Y. Mishina, E. M. Duquid, C. He, “Direct reversal of DNA alkylation damage” Chem. Rev. 2006, 106, 215-232.
129. C. He, J.-C. Hus, L. J. Sun, P. Zhou, D. P. G. Norman, V. Dötsch, H. Wei, J. D. Gross, W. S. Lane, G. L. Wagner, G. L. Verdine, “A methylation-dependent electrostatic switch controls DNA repair and transcriptional activation by E. coli Ada” Mol. Cell, 2005, 20, 117-129.
130. C. C. García, M. Djavani, I. Topisirovic, K. L. B. Borden, M. S. Salvato, E. B. Damonte, “Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds” J. Gen. Virol. 2006, 87, 1217-1228.
131. R. N. De Guzman, Z. R. Wu, C. C. Stalling, L. Pappalardo, P. N. Borer, M. F. Summers, “Structure of the HIV-1 nucleocapsid protein bound to the SL3 Ψ-RNA recognition element” Science, 1998, 279, 384-388.
132. R. A. Musah, “The HIV-1 nucleocapsid zinc finger protein as a target of antiretroviral therapy” Curr. Top. Med. Chem. 2004, 4, 1605-1622.
133. A. I. Anzellotti, Q. Liu, M. Bloemink, J. N. Scarsdale, N. Farrell, “Targeting retroviral Zn finger-DNA interactions: a small-molecule approach using the electrophilic nature of trans-Platinum-nucleobase compounds” Chem. Biol. 2006, 13, 539-548.
134. J. Duan, L. Nilsson, “Effect of Zn2+ on DNA recognition and stability of the p53 DNA-binding domain” Biochemistry, 2006, 45, 7483-7492.
135. J. M. Canadillas, H. Tidow, S. M. Freund, T. J. Rutherford, H. C. Ang, A. R. Fersht, “Solution structure of p53 core domain: structural basis for its instability” Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 7, 2109-2114.
136. M. Kitayner, H. Rozenberg, N. Kessler, D. Rabinovich, L. Shaulov, T. E. Haran, Z. Shakked, “Structural basis of DNA recognition by p53 tetramers” Mol. Cell, 2006, 22, 741-753.
137. S. L. Harris, A. J. Levine, “The p53 pathway: positive and negative feedback loops” Oncogene, 2005, 24, 2899-2908.
138. T. Soussi, “The p53 pathway and human cancer” Br. J. Surg. 2005, 92, 1331-1332.
139. T. Ozaki, A. Nakagawara, “P73, a sophisticated p53 family member in the cancer world” Cancer Sci. 2005, 96, 729-737.
140. P. A. Hall, W. G. McCluggage, “Assessing p53 in clinical contexts: unlearned lessons and new perspectives” J. Pathol. 2006, 208, 1-6.
141. K. H. Vousden, D. P. Lane, “p53 in health and disease” Nat. Rev. Mol. Cell Biol. 2007, 8, 4, 275-283.
142. B. P. Bouchet, C. C. de Fromentel, A. Puisieux, C. M. Galmarini, “p53 as a target for anti-cancer drug development” Crit. Rev. Oncol. Hematol. 2006, 58, 190-207.
143. V. J. N. Bykov, G. Selivanova, K. G. Wiman, “Small molecules that reactivate mutant p53” Eur. J. Cancer, 2003, 39, 1828-1834.
144. A. Friedler, B. S. DeDecker, S. M. V. Freund, C. Blair, S. Rüdiger, A. R. Fersht, “Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for mutant conformation” J. Mol. Biol. 2004, 336, 187-96.
145. V. J. N. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K. G. Wiman, G. Selivanova, “Restoration of the tumor suppressor function to mutant p53 by a low molecular-weight compound” Nat. Med. 2002, 8, 282-288.
146. N. Pietrancosta, “A. Moumen, R. Dono, P. Lingor, V. Planchamp, F. Lamballe, M. Bähr, J.-L. Kraus, F. Maina, Imino-tetrahydro-benzothiazole derivatives as p53 inhibitors: discovery of a highly potent in vivo inhibitor and its action mechanism” J. Med. Chem. 2006, 49, 3645-3652.
147. V. J. N. Bykov, G. Selivanova, K. G. Wiman, “Small molecules that reactivate mutant p53” Eur. J. Cancer, 2006, 39, 1828-1834.
148. A. Friedler, L. O. Hansson, D. B. Veprintsev, S. M. V. Freund, T. M. Rippin, P. V. Nikolova, M. R. Proctor, S. Rüdiger, A. R. Fersht, “A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants” Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 937-942.
149. T. Hara, S. Durell, M. C. Myers, D. H. Apella, “Probing the structural requirements of peptoids that inhibit HDM2–p53 interactions” J. Am. Chem. Soc. 2006, 128, 1995-2004.
150. P. H. Kussie, S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A. J. Levine, N. P. Pavletich, “Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain” Science, 1996, 274, 921-922.
151. P. Hainaut, K. Mann, “Zinc binding and redox control of p53 structure and function” Antioxid. Redox Signaling, 2001, 3, 611-623.
152. C. Meplan, M. J. Richard, “Redox signalling and transition metals in the control of the p53 pathway” Biochem. Pharmacol. 2000, 59, 25-33.
153. R. Zhao, R. P. Planalp, R. Ma, B. T. Greene, B. T. Jones, M. W. Brechbiel, F. M. Torti, S. V. Torti, “Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator” Biochem. Pharmacol. 2004, 67, 1677-1688.
154. G. Filomeni, G. Cerchiaro, A. M. Da Costa Ferreira, A. De Martino, J. Z. Pedersen, G. Rotilio, M. R. Ciriolo, “Pro-apoptotic activity of novel isatin-Schiff base copper(II) complexes depends on oxidative stress induction and organelle-selective damage” J. Biol. Chem. 2007, 282, 12010-12021.
155. J. Y. Duffy, C. M. Miller, G. L. Rutschilling, G. M. Ridder, M. S. Clegg, C. L. Keen, G. P. Daston, “A decrease in intracellular zinc level precedes the detection of early indicators of apoptosis in HL-60 cells” Apoptosis, 2001, 6, 161-172.
156. E. Kimura, S. Aoki, E. Kikuta, T. Koike, “Bioinorganic chemistry special feature: a macrocyclic zinc(II) fluorophore as a detector of apoptosis” Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 3731-3736.
157. W. Maret, C. Jacob, B. L. Vallee, E. H. Fischer, “Inhibitory sites in enzymes: zinc removal and reactivation by thionein” Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 1936-1940.
158. J. T. Bukrinski, M. J. Bjerrum, A. Kadziola, “Native carboxypeptidase A in a new crystal environment reveals a different conformation of the important tyrosine 248” Biochemistry, 1998, 37, 16555-16564.
159. W. Maret, C. A. Yetman, L. Jiang, “Enzyme regulation by reversible zinc inhibition glycerol: phosphate dehydrogenase as an example” Chem.–Biol. Interact. 2001, 130–132, 891-901.
160. D. K. Perry, M. J. Smyth, H. R. Stennicke, G. S. Salvensen, P. Duriez, G. G. Poirier, Y. A. Hannun, “Zinc is potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis” J. Biol. Chem. 1997, 272, 18530-18533.
161. A. Krezel, W. Maret, “Dual nanomolar and picomolar Zn(II) binding properties of metallothionein” J. Am. Chem. Soc. 2007, 129, 10911-10921.
162. K. Garber, “HDAC Inhibitors overcome first hurdle” Nat. Biotechnol. 2007, 25, 17-19.